• 1
    Op den Buijsch RAM, van de Plas A, Stolk LML, Christiaans MHL, van Hooff JP, Undre NA, van Dieijen-Visser MP, Bekers O. Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol 2007; 63: 10391044.
  • 2
    Kahan BD, Keown IP, Levy GA, Johnston A. Therapeutic Drug Monitoring of Immunosuppressant Drugs in Clinical Practice. Clin Ther 2002; 24: 330350.
  • 3
    van Gelder T, Hesselink DA. Dosing Tacrolimus Based on CYP3A5 Genotype: will It Improve Clinical Outcome? Clin Pharmacol Ther 2010; 87: 640641.
  • 4
    Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 2011; 72: 948957.
  • 5
    Scholten EM, Cremers SCLM, Schoemaker RC, Rowshani AT, van Kan EJ, Den Hartigh J, Paul LC, De Fijter JW. AUC-guided dosing of tacrolimus prevents systemic overexposure in renal transplant recipients. Kidney Int 2005; 67: 24402447.
  • 6
    Barraclough KA, Isbel NM, Kirkpatrick CM, Lee KJ, Taylor PJ, Johnson DW, Campbell SB, Leary DR, Staatz CE. Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol 2011; 71: 207223.
  • 7
    Ware N, MacPhee IAM. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation. Curr Opin Mol Ther 2010; 12: 270283.
  • 8
    Birdwell KA, Grady B, Choi L, Xu H, Bian A, Denny JC, Jiang M, Vranic G, Basford M, Cowan JD, Richardson DM, Robinson MP, Ikizler TA, Ritchie MD, Stein CM, Haas DW. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genomics 2012; 22: 3242.
  • 9
    Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383391.
  • 10
    MacPhee IAM, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW. Tacrolimus Pharmacogenetics: polymorphisms associated with expression of Cytochrome P4503A5 and P-Glycoprotein correlate with Dose Requirement. Transplantation 2002; 74: 14861489.
  • 11
    Li D, Gui R, Li J, Huang Z, Nie X. Tacrolimus Dosing in Chinese Renal Transplant Patients Is Related to MDR1 Gene C3435T Polymorphisms. Transplant Proc 2006; 38: 28502852.
  • 12
    MacPhee IAM, Fredericks S, Mohamed M, Moreton M, Carter ND, Johnston A, Goldberg L, Holt DW. Tacrolimus Pharmacogenetics: the CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians. Transplantation 2005; 79: 499502.
  • 13
    de Wildt SN, van Schaik RH, Soldin OP, Soldin SJ, Brojeni PY, van der Heiden IP, Parshuram C, Nulman I, Koren G. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur J Clin Pharmacol 2011; 67: 12311241.
  • 14
    Gijsen V, Mital S, van Schaik RH, Soldin OP, Soldin SJ, van der Heiden IP, Nulman I, Koren G, de Wildt SN. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant 2011; 30: 13521359.
  • 15
    Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Provôt F, Hazzan M, Noël C, Broly F, Cauffiez C. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant 2011; 26: 30463050.
  • 16
    Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245254.
  • 17
    Wehland M, Bauer S, Brakemeier S, Burgwinkel P, Glander P, Kreutz R, Lorkowski C, Slowinski T, Neumayer HH, Budde K. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011; 21: 179184.
  • 18
    Zheng HX, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, McDade K, Zhang J, Burckart GJ. Tacrolimus Dosing in Adult Lung Transplant Patients is Related to Cytochrome P4503A5 Gene Polymorphism. J Clin Pharmacol 2004; 44: 135140.
  • 19
    Fredericks S, Moreton M, Reboux S, Carter ND, Goldberg L, Holt DW, MacPhee IAM. Multidrug Resistance Gene-1 (MDR-1) Haplotypes Have a Minor Influence on Tacrolimus Dose Requirements. Transplantation 2006; 82: 705708.
  • 20
    Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 15741583.
  • 21
    De Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DRJ. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 2011; 12: 12811291.
  • 22
    Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour DC, Malaise J, Lison D, Mourad M. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 2006; 6: 27062713.
  • 23
    Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C. Optimization of initial tacrolimus dose using pharmacogenetic testing. Pharmacol Ther 2010; 87: 721726.
  • 24
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307310.
  • 25
    Tacrolimus II. 2007. Abbott Laboratories Diagnostic Division, Abbott, IL, 60064, USA.Phone:+1-877-4ABBOTT.
  • 26
    Syva. Emit 2000 Tacrolimus Assay. 2008. Siemens Healthcare Diagnostics Inc, 511 Benedict Avenue, Tarrytown, NY 10591, USA. Phone: +1 914 631-8000.
  • 27
    Fredericks S, Moreton M, MacPhee IA, Mohamed M, Marlowe S, Jorga A, Johnston A, Carter ND, Holt DW. Genotyping cytochrome P450 3A5 using the Light Cycler. Ann Clin Biochem 2005; 42: (Pt 5): 376381.
  • 28
    Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ, Christians U. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 2431.
  • 29
    Benkali K, Prémaud A, Picard N, Rérolle JP, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, Rousseau A. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009; 48: 805816.